66215-71-2

Usage

Uses

Used in Pharmaceutical Research:
(Z)-2-Methoxyimino-2-[2-(tritylamino)thiazol-4-yl]acetic acid is used as a research compound for exploring its potential pharmaceutical applications. Its unique structure, which includes a thiazole ring and a tritylamino group, may offer novel interactions with biological targets, making it a promising candidate for the development of new drugs.
Used in Synthesis of Other Compounds:
In addition to its potential pharmaceutical applications, (Z)-2-Methoxyimino-2-[2-(tritylamino)thiazol-4-yl]acetic acid may also serve as a building block for the synthesis of other complex organic compounds. Its versatile structure could be utilized in the creation of new molecules with various applications in different industries, such as materials science, agrochemicals, or specialty chemicals.

Upstream product

• 76-83-5 trityl chloride 
• 91868-79-0 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetic acid 

Downstream Products

• 87791-70-6 ((2S,3S)-3-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-2-methyl-4-oxo-azetidin-1-yl)-phosphonic acid dibenzyl ester 
• 122692-95-9 (3S,7aR)-6-{2-[(Z)-Methoxyimino]-2-[2-(trityl-amino)-thiazol-4-yl]-acetyl}-2,2-dimethyl-5-oxo-hexahydro-imidazo[5,1-b]thiazole-3-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester 
• 122692-96-0 (3S,7aR)-6-{2-[(Z)-Methoxyimino]-2-[2-(trityl-amino)-thiazol-4-yl]-acetyl}-2,2-dimethyl-5-oxo-hexahydro-imidazo[5,1-b]thiazole-3-carboxylic acid 4-methoxy-benzyl ester 
• 114586-19-5 2-(2-tritylamino-4-thiazolyl)-2-(methoxy-imino)acetyl chloride 
• 87791-68-2 2-[(Z)-Methoxyimino]-N-((2S,3S)-2-methyl-4-oxo-azetidin-3-yl)-2-[2-(trityl-amino)-thiazol-4-yl]-acetamide 

Relevant academic research and scientific papers

Synthetic approach to gain insight into antigenic determinants of cephalosporins: In vitro studies of chemical structure-IgE molecular recognition relationships

Cephalosporins, after penicillins, are the most widely used antibacterial agents in infectious diseases and the cause of adverse immune reactions in the world. Whether a patient with a suspected allergy to a β-lactam can safely take a cephalosporin is often a matter of debate. However, there are no tests with enough sensitivity to detect allergy to cephalosporins. Understanding the way in which the drug metabolizes after protein conjugation is important if we are to make advances in the diagnosis of clinical allergy. Structural studies of cephalosporin-protein adducts have never been addressed successfully and are difficult to investigate. Our approach to determine the requirements involved in antigenic determinant structures consisted of designing and synthesizing a proposed skeleton that remains linked to the carrier protein after chemical degradation in cephalosporin conjugated to carrier proteins. In this study, a series of proposed epitopes were efficiently synthesized following a versatile methodology, involving the condensation of the R1 acyl side chains of native cephalosporins, with the nuclear fragment structures (derived from amino acids or other aminofunctionalized molecules). The final well-defined structures 1-4 (a-f), representing a fragment from the proposed cephalosporin-Lys(protein) adduct intermediate, consist of closely related low-molecular-weight molecules, differing only in the functional group at C-3 and the R1 side chains. They were assessed with sera from patients allergic to cephalosporins to study structure-IgE molecular recognition relationships. These IgE showed an enhanced recognition to proposed new skeleton epitopes with adequate functionality at C-3, with the specifities mainly related to the R1 acyl side chain. Thus, this study led us to refine the model haptenic structures of cephalosporins and gain insight into the chemical mechanism of epitope formation.

Novel cephalosporin derivatives, processes for their preparation and pharmaceutical compositions containing them

The invention relates to novel 7β-[2-(2-amino-thiazol-4-yl)-(Z)-2-alkoxyimino-acetamido]-3-[(2--mercapto-1,3,4-thiadiazol-5-yl)thiomethyl]-ceph-3-em--4-carboxylic acids of the formula wherein R represents a C1-4alkyl group, and pharmaceutically acceptable salts and esters thereof. The antibacterial compounds of the invention can be prepared by methods well known in the cephalosporin chemistry.

3-Acetoxymethyl-7-(iminoacetamido)-cephalosporanic acid derivatives

Compounds of the formula STR1 wherein R is selected from the group consisting of hydrogen and groups easily removable by acid hydrolysis or hydrogenolysis, R' is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, alkenyl and alkynyl of 2 to 4 carbon atoms and groups easily removable by acid hydrolysis or hydrogenolysis, A is selected from the group consisting of hydrogen, alkali metal and equivalents of an alkaline earth metal or magnesium and an organic amine base with the proviso that when R' is a group easily removable by acid hydrolysis or hydrogenolysis, R is also and when R' is hydrogen, R also is hydrogen and the wavy line means the OR' group may be in either one of the two possible syn or anti positions having antibiotic activity and process for their preparation.